Acer Therapeutics Raises Over $2.675 Million in At-the-Market Offering Under Nasdaq Rules

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company dedicated to bringing therapies to those suffering from serious, rare and life-threatening diseases, has entered into a definitive agreement to purchase 2,920,306 shares of its own common stock (or common stock equivalent) at a price of $0.916 per share, in a registered direct offering.

Furthermore, in a concurrent private placement, the company will issue warrants to purchase up to the same amount of stock, with an exercise price of $0.791 per share and a term of five and a half years. This is a great opportunity for investors to gain exposure to Acer Therapeutics’ potential for success in providing life-saving treatments.

H.C. Wainwright & Co. is proud to serve as the exclusive placement agent for this exciting offering. They are committed to providing the best service possible to ensure the success of the offering.

The Company is delighted to announce that it will soon be closing its offering on or around March 24, 2023, pending the satisfaction of customary closing conditions. This offering is estimated to bring in approximately $2.675 million in gross proceeds, before deducting placement agent’s fees and other offering expenses payable by the Company. The Company will be putting these funds to use for general corporate purposes and working capital. We look forward to seeing the positive results this investment will bring.

The Company is offering shares of its common stock through a “shelf” registration statement on Form S-3 (File No. 333-261342) filed with the Securities and Exchange Commission (SEC) and declared effective on December 7, 2021.

All offering of shares of common stock is made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Interested investors can obtain a final prospectus supplement and accompanying prospectus relating to the registered direct offering from the SEC’s website when it becomes available.

The warrants and underlying shares of common stock offered in this private placement are not registered under the Securities Act of 1933, or applicable state securities laws, and can only be reoffered or resold in the United States with an effective registration statement or an applicable exemption. Don’t miss this opportunity to get in early on a potentially lucrative investment!

We are pleased to announce an exciting opportunity to invest in these securities! However, before investing, potential buyers should be sure to register or qualify under the securities laws of their state or jurisdiction. Don’t miss out on this great chance to diversify your portfolio and gain financial success!

About Acer Therapeutics

Acer is a pharmaceutical powerhouse that is dedicated to providing innovative treatments for rare and life-threatening diseases that have yet to be addressed. Their FDA-approved OLPRUVA™ (sodium phenylbutyrate) is a game-changer for Urea Cycle Disorders (UCDs) involving specific deficiencies.

Acer is also researching additional treatments that could revolutionize the way we care for patients with rare conditions, such as Maple Syrup Urine Disease (MSUD), Vascular Ehlers-Danlos Syndrome (vEDS), Vasomotor Symptoms (VMS), Post-Traumatic Stress Disorder (PTSD), and prostate cancer. With Acer, a brighter future for those suffering from rare and life-threatening diseases is just around the corner.

Leave a Comment